Table 2.

Association of adiponectin and c-peptide levels with prostate cancer in CPS-II

	All aggressive^a			High risk^b
Analyte	Cases	Controls	OR (95% CI)	Cases	Controls	OR (95% CI)
Adiponectin (ng/mL)
<6,178	62	68	1.00 (ref)	43	38	1.00 (ref)
6,178–<7,879	61	68	1.05 (0.62–1.78)	38	43	0.76 (0.38–1.52)
7,879–<11,109	86	68	1.43 (0.87–2.36)	55	43	1.10 (0.58–2.11)
≥11,109	63	68	1.11 (0.64–1.93)	36	48	0.70 (0.33–1.49)
P trend			0.59			0.56
c-peptide (ng/mL)
<2.95	72	68	1.00 (ref)	43	47	1.00 (ref)
2.95–<4.69	59	68	0.69 (0.42–1.16)	34	41	0.94 (0.48–1.82)
4.69–<6.55	60	68	0.77 (0.47–1.28)	39	42	0.95 (0.48–1.87)
≥6.55	80	67	1.18 (0.69–2.02)	55	41	1.41 (0.72–2.78)
P trend			0.44			0.31

NOTE: Model stratified on pairs and adjusted for family history of prostate cancer, body mass index, physical activity in metabolic equivalents (METs), total calcium intake, and energy intake.

↵^aGleason score ≥7 (4+3) or T3 or T4 or death from prostate cancer.
↵^bGleason score ≥8 or stage T3 or T4.